Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DMV (Doxil, Melphalan, Velcade) in Relapsed/Refractory Multiple Myeloma
NCT00516191Phase 2Withdrawn
- Sponsor
- University of California, San Francisco
- Start
- Oct 2004
- Primary completion
- Oct 2010
- Modality
- Modified Peptides, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin, melphalan and bortezomib in multiple myeloma (MM), sponsored by University of California, San Francisco. Primary endpoints: Safety and Tolerability at 6 years and Maximum Tolerated Dose at 6 years. Planned start Oct 2004; status: withdrawn.
02
Drugs
pegylated liposomal doxorubicinmelphalanbortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00516191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00516191.